These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1736805)

  • 1. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
    O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
    Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective evaluation of CA15-3 in stage I carcinoma of the breast.
    O'Hanlon DM; Kerin MJ; Kent PJ; Skehill R; Maher D; Grimes H; Given HF
    J Am Coll Surg; 1995 Feb; 180(2):210-2. PubMed ID: 7850057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis.
    Diel IJ; Solomayer EF; Seibel MJ; Pfeilschifter J; Maisenbacher H; Gollan C; Pecherstorfer M; Conradi R; Kehr G; Boehm E; Armbruster FP; Bastert G
    Clin Cancer Res; 1999 Dec; 5(12):3914-9. PubMed ID: 10632320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer.
    Horobin JM; Browning MC; McFarlane NP; Smith G; Preece PE; Wood RA; Cuschieri A
    J R Coll Surg Edinb; 1991 Aug; 36(4):219-21. PubMed ID: 1941734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
    Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
    Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical usefulness of tumor markers in breast cancer].
    Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
    Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
    Oremek G; Sauer-Eppel H; Klepzig M
    Anticancer Res; 2007; 27(4A):1961-2. PubMed ID: 17649805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of TPS and CA 15-3 assays for monitoring chemotherapy in metastatic breast cancer patients.
    Einarsson R; Lindman H; Bergh J
    Anticancer Res; 2000; 20(6D):5089-93. PubMed ID: 11326674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunoradiometric assay of tumor marker CA15-3 and its clinical application].
    Chen Z; Fan Z; Yang J
    Zhonghua Zhong Liu Za Zhi; 1998 Mar; 20(2):125-8. PubMed ID: 10920962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients.
    Kurebayashi J; Nomura T; Hirono M; Okubo S; Udagawa K; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Sonoo H
    Jpn J Clin Oncol; 2006 Mar; 36(3):150-3. PubMed ID: 16520359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Considerations in rational use of tumor markers in breast carcinoma].
    Crombach G
    Praxis (Bern 1994); 1998 Apr; 87(17):589-94. PubMed ID: 9623326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients].
    Loibl S; Königs A; Kaufmann M; Costa SD; Bischoff J
    Zentralbl Gynakol; 2006 Dec; 128(6):330-5. PubMed ID: 17213971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer.
    Tondini C; Hayes DF; Gelman R; Henderson IC; Kufe DW
    Cancer Res; 1988 Jul; 48(14):4107-12. PubMed ID: 3164256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer.
    Martín A; Corte MD; Alvarez AM; Rodriguez JC; Andicoechea A; Bongera M; Junquera S; Pidal D; Allende T; Muñiz JL; Vizoso F
    Anticancer Res; 2006; 26(5B):3965-71. PubMed ID: 17094428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.